Outcome of Adolescents and Young Adults Compared With Pediatric Patients With Acute Myeloid and Promyelocytic Leukemia
| Autor: | Syed Sameer Nasir, Smith Giri, Michael Martin, Sara Nunnery |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Acute promyelocytic leukemia
Adult Male Cancer Research medicine.medical_specialty Pediatrics Myeloid Multivariate analysis Adolescent Antineoplastic Agents Disease-Free Survival 03 medical and health sciences Young Adult 0302 clinical medicine Leukemia Promyelocytic Acute Internal medicine Epidemiology Medicine Humans Registries Young adult Child neoplasms business.industry Mortality rate Infant Newborn Myeloid leukemia Infant Hematology medicine.disease humanities Leukemia Leukemia Myeloid Acute medicine.anatomical_structure Logistic Models Treatment Outcome Oncology 030220 oncology & carcinogenesis Child Preschool Multivariate Analysis Female business 030215 immunology SEER Program |
| Zdroj: | Clinical lymphoma, myelomaleukemia. 17(2) |
| ISSN: | 2152-2669 |
| Popis: | Studies on the outcome of adolescents and young adults (AYAs) with acute myeloid leukemia (AML) and acute promyelocytic leukemia (APL) are limited.We compared the outcome of AYA (19-30 years) patients with AML and PML and pediatric (0-18 years) patients with AML (pAMLs) and APL (pAPLs) utilizing the Surveillance Epidemiology and End Results-18 registry. Early mortality rate (EMR), defined as mortality within 1 month of diagnosis, was used as a surrogate for treatment-related mortality. Survival statistics were computed using the Kaplan-Meier method. Multivariate analysis was done using logistic regression and the Cox proportional hazard regression model.A total of 6343 patients with AML were identified; 44.7% were AYAs. pAMLs had lower EMR (6.2% vs. 9.2%; P .01) and higher overall survival (OS) (1-year, 70.3% vs. 62.1%; 5-year, 48.2% vs. 36.4%; P .01). Nine hundred twenty patients with APL were also identified; 59.5% were AYAs. No statistically significant difference was found between AYAs with APL and pAPLs in EMR (11.4% vs. 14.1%; P = .23) and OS (1-year, 83.8% vs. 81.2%; P = .31 and 5-year, 68.2% vs. 73.1%; P = .11]. Comparing all patients with AML and APL, AYAs with APL and pAPLs had higher EMR (11.4% and 14.1% vs. 6.2% and 9.2%; P ≤ .01) but better OS than AYAs with AML and pAMLs (5-year OS, 68.2% and 73.1% vs. 48.2% and 36.4%; P ≤ .01).Our analysis shows AYAs with AML have worse EMR and OS compared with pAMLs. AYAs with APL and pAPLs have similar outcomes. To our knowledge, this is the first study reporting outcomes of AYAs with APL and pAPLs using a large population-based registry and their comparison with same age patients with AML. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect